Search results: (10000)
News Use of Targeted Therapy with Dupilumab in Patients with Allergic Diseases
Interleukins (IL) 4 and 13 play an important role in the pathogenesis of allergic diseases. Their blockade is therefore a suitable strategy for a number of these conditions. This is offered by the new monoclonal antibody dupilumab (Dupixent), which is approved for the treatment of atopic dermatitis, asthma with type 2 inflammation, and chronic rhinosinusitis with nasal polyposis. Studies are ongoing to evaluate its efficacy in other diseases where type 2 inflammation predominates.
News Asthma is not a risk factor for a severe course of COVID-19
According to the statement of the Czech Initiative for Asthma from April 2020, the disease COVID-19 caused by the new type of coronavirus does not pose significantly greater danger for people with asthma than for the general population. It is, however, necessary to adhere to the prescribed treatment and keep asthma under control. The Journal of Allergy and Clinical Immunology provides an explanation for this surprising phenomenon. It is the reduced expression of ACE2 receptors in people with asthma and allergies, as shown by a new study involving three cohorts of pediatric and adult patients. The SARS-CoV-2 virus uses ACE2 receptors to enter the host cell.
News Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven activating mutation of the epidermal growth factor receptor (EGFR) gene, who developed resistance to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib during treatment. After the secondary mutation EGFR T790M was confirmed, osimertinib, a third-generation EGFR TKI, was introduced, resulting in disease regression, which is ongoing. This case study illustrates the significance of the role of osimertinib in the treatment of patients with NSCLC with an activating EGFR mutation, whose disease progresses during treatment with first and second-generation EGFR TKIs due to the emergence of the secondary EGFR T790M mutation.
News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.
News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.
News Alzheimer's Disease: Diagnosis Step by Step in 4 Points
Alzheimer's disease is the most common cause of dementia. With the aging population, this topic is becoming increasingly relevant. How have the knowledge and diagnostic possibilities of the disease progressed over the past decades?
News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis
The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.
News Prokinetics in the Treatment of Diabetic Gastroparesis
One of the common complications of diabetes mellitus is a motility disorder of the gastrointestinal tract, which can affect any part of the digestive tube, and therefore has various forms. Among these therapeutically challenging conditions is diabetic gastroparesis, which involves impaired stomach emptying.
News Options for Anticoagulant Therapy During Catheter Ablation for Atrial Fibrillation: Safety and Efficiency of Bridging with Dabigatran Compared to Interruption of NOACs
Catheter ablation is an established method for treating supraventricular and ventricular arrhythmias. Patients with atrial fibrillation should also use anticoagulant therapy to prevent thromboembolic events, even during ablation. The number of patients being treated with new anticoagulants (NOACs) is increasing, but the use of direct factor Xa inhibitors poses a risk of life-threatening bleeding during catheterization if a specific antidote is not available at the healthcare facility. Options to prevent this complication include short-term switching to dabigatran or complete interruption of NOACs therapy with temporary heparin support. The aim of the presented study was to compare the safety and feasibility of both methods.
News Pregabalin in Seniors Confirmed Its Safety and Effectiveness
A pooled analysis of 11 studies investigated the safety and effectiveness of pregabalin in seniors with neuropathic pain. Are the outcomes in these indicators different for older individuals than in the general population sample?
News Induction vs. Escalation Treatment: Which Strategy to Choose in the Therapy of Multiple Sclerosis?
Opinions on the optimal therapy for multiple sclerosis (MS) are constantly evolving, and experts are debating the most appropriate first-line treatment strategy. A British cohort study focused on the long-term outcomes of induction and escalation therapies, two key approaches in the treatment of MS.
News Tolerability and Efficacy of Eye Drops with and without Preservatives − A Comparison in Routine Clinical Practice
Insufficient patient compliance due to intolerance of the ocular preparation is a major reason for changing treatment, such as switching to preservative-free drops. The aim of the international prospective and observational study was to assess the efficacy and local tolerability within a one-year therapy of preservative-free latanoprost compared to drops containing preservatives and to determine patient satisfaction at the midpoint of treatment. During the monitoring, 3 examinations were planned: one at the study entry and two follow-up visits (at 6 and 12 months).
News In vivo monitoring of corneal changes in patients treated with and without preservative-containing glaucoma medications
A study published last year by Italian authors monitored structural changes in the corneas of patients treated with preservative-free glaucoma medication for 3 years using confocal microscopy and compared them with changes observed in patients treated with preservative-containing medications.
News IPFchecker Project Helps Detect Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a serious progressive disease of the lung tissue of unclear etiology. Highly effective antifibrotic therapy is used in treatment, which can significantly prolong the lives of patients. However, timely detection of the disease is necessary for treatment success. For this purpose, the IPFchecker web application has been created, which helps radiologists and pulmonologists with more accurate diagnosis and timely detection of the disease.
News Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
Authors of a recently published study attempted to determine the value of minimum and optimal levels of coagulation factors in patients with severe hemophilia who engage in physical activities.